Cargando…

Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples

BACKGROUND: Increasing evidence linking epigenetic mechanisms and different diseases, including cancer, has prompted in the last 15 years the investigation of histone post-translational modifications (PTMs) in clinical samples. Methods allowing the isolation of histones from patient samples followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Noberini, Roberta, Savoia, Evelyn Oliva, Brandini, Stefania, Greco, Francesco, Marra, Francesca, Bertalot, Giovanni, Pruneri, Giancarlo, McDonnell, Liam A., Bonaldi, Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317427/
https://www.ncbi.nlm.nih.gov/pubmed/34315505
http://dx.doi.org/10.1186/s13148-021-01120-7
_version_ 1783730069302149120
author Noberini, Roberta
Savoia, Evelyn Oliva
Brandini, Stefania
Greco, Francesco
Marra, Francesca
Bertalot, Giovanni
Pruneri, Giancarlo
McDonnell, Liam A.
Bonaldi, Tiziana
author_facet Noberini, Roberta
Savoia, Evelyn Oliva
Brandini, Stefania
Greco, Francesco
Marra, Francesca
Bertalot, Giovanni
Pruneri, Giancarlo
McDonnell, Liam A.
Bonaldi, Tiziana
author_sort Noberini, Roberta
collection PubMed
description BACKGROUND: Increasing evidence linking epigenetic mechanisms and different diseases, including cancer, has prompted in the last 15 years the investigation of histone post-translational modifications (PTMs) in clinical samples. Methods allowing the isolation of histones from patient samples followed by the accurate and comprehensive quantification of their PTMs by mass spectrometry (MS) have been developed. However, the applicability of these methods is limited by the requirement for substantial amounts of material. RESULTS: To address this issue, in this study we streamlined the protein extraction procedure from low-amount clinical samples and tested and implemented different in-gel digestion strategies, obtaining a protocol that allows the MS-based analysis of the most common histone PTMs from laser microdissected tissue areas containing as low as 1000 cells, an amount approximately 500 times lower than what is required by available methods. We then applied this protocol to breast cancer patient laser microdissected tissues in two proof-of-concept experiments, identifying differences in histone marks in heterogeneous regions selected by either morphological evaluation or MALDI MS imaging. CONCLUSIONS: These results demonstrate that analyzing histone PTMs from very small tissue areas and detecting differences from adjacent tumor regions is technically feasible. Our method opens the way for spatial epi-proteomics, namely the investigation of epigenetic features in the context of tissue and tumor heterogeneity, which will be instrumental for the identification of novel epigenetic biomarkers and aberrant epigenetic mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01120-7.
format Online
Article
Text
id pubmed-8317427
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83174272021-07-30 Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples Noberini, Roberta Savoia, Evelyn Oliva Brandini, Stefania Greco, Francesco Marra, Francesca Bertalot, Giovanni Pruneri, Giancarlo McDonnell, Liam A. Bonaldi, Tiziana Clin Epigenetics Methodology BACKGROUND: Increasing evidence linking epigenetic mechanisms and different diseases, including cancer, has prompted in the last 15 years the investigation of histone post-translational modifications (PTMs) in clinical samples. Methods allowing the isolation of histones from patient samples followed by the accurate and comprehensive quantification of their PTMs by mass spectrometry (MS) have been developed. However, the applicability of these methods is limited by the requirement for substantial amounts of material. RESULTS: To address this issue, in this study we streamlined the protein extraction procedure from low-amount clinical samples and tested and implemented different in-gel digestion strategies, obtaining a protocol that allows the MS-based analysis of the most common histone PTMs from laser microdissected tissue areas containing as low as 1000 cells, an amount approximately 500 times lower than what is required by available methods. We then applied this protocol to breast cancer patient laser microdissected tissues in two proof-of-concept experiments, identifying differences in histone marks in heterogeneous regions selected by either morphological evaluation or MALDI MS imaging. CONCLUSIONS: These results demonstrate that analyzing histone PTMs from very small tissue areas and detecting differences from adjacent tumor regions is technically feasible. Our method opens the way for spatial epi-proteomics, namely the investigation of epigenetic features in the context of tissue and tumor heterogeneity, which will be instrumental for the identification of novel epigenetic biomarkers and aberrant epigenetic mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01120-7. BioMed Central 2021-07-28 /pmc/articles/PMC8317427/ /pubmed/34315505 http://dx.doi.org/10.1186/s13148-021-01120-7 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Noberini, Roberta
Savoia, Evelyn Oliva
Brandini, Stefania
Greco, Francesco
Marra, Francesca
Bertalot, Giovanni
Pruneri, Giancarlo
McDonnell, Liam A.
Bonaldi, Tiziana
Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title_full Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title_fullStr Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title_full_unstemmed Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title_short Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
title_sort spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317427/
https://www.ncbi.nlm.nih.gov/pubmed/34315505
http://dx.doi.org/10.1186/s13148-021-01120-7
work_keys_str_mv AT noberiniroberta spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT savoiaevelynoliva spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT brandinistefania spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT grecofrancesco spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT marrafrancesca spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT bertalotgiovanni spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT prunerigiancarlo spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT mcdonnellliama spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples
AT bonalditiziana spatialepiproteomicsenabledbyhistoneposttranslationalmodificationanalysisfromlowabundanceclinicalsamples